Overview
Overview
Functional vascular endothelial cells differentiated from UCT-WJ-MSCs; producing nitric oxide, VEGF, and angiopoietins for blood vessel formation, vascular repair, and blood pressure regulation
FOR RESEARCH USE AND INTERNATIONAL USE ONLY
| Source & Manufacturing |
|---|
| Derived from P2 UCT-WJ-MSCs via endothelial differentiation |
| VEGF-A bFGF EGF in fibronectin-coated conditions |
| DMSO-free cryopreservation |
| Post-thaw viability 95% |
| Markers: CD31⁺ (PECAM-1), VE-Cadherin⁺, vWF⁺ (von Willebrand Factor), eNOS⁺, VEGFR2⁺ |
| Tube formation assay on Matrigel confirms angiogenic competence prior to release |
Clinical Overview
Clinical Overview
Endothelial dysfunction is a unifying pathological mechanism in cardiovascular disease, diabetes complications, chronic wounds, erectile dysfunction, and ischemic stroke. Akira Endothelial Cells restore vascular homeostasis through three complementary mechanisms: direct incorporation into new blood vessels (vasculogenesis), paracrine stimulation of angiogenesis in ischemic tissue, and restoration of endothelial-derived vasoprotective molecules (NO, prostacyclin) that regulate vascular tone and prevent thrombosis. UCT-WJ-MSC-derived endothelial cells form more patent tube networks than adult endothelial sources in Matrigel assays — reflecting the developmental potency advantage of perinatal origin.[1] Their delivery (IV, intra-arterial, or direct injection) has demonstrated efficacy in restoring blood flow in peripheral arterial disease models and reducing hypertension-induced vascular remodeling.
Process
Mechanism of Action
Vasculogenesis: CD31+/VE-Cadherin+ endothelial cells directly incorporate into nascent capillaries in ischemic tissue, establishing new microvascular networks that restore perfusion to hypoxic zones.
NO Synthesis & Vasoregulation: eNOS (endothelial nitric oxide synthase) generates NO from L-arginine, causing vascular smooth muscle relaxation (vasodilation), inhibition of platelet aggregation, and anti-inflammatory effects on vessel walls. This directly addresses hypertension, endothelial dysfunction, and atherosclerosis risk.
Angiogenic Paracrine Signaling: VEGF-A, Ang-1, EGF, HGF, and PDGF secretion activates endothelial proliferation, migration, and lumen formation in surrounding pericyte-coated vessels — amplifying neovascularization beyond transplanted cell count.
Barrier Restoration: Akira Endothelial Cells upregulate tight junction proteins (claudin-5, occludin, ZO-1) to restore vascular barrier integrity after ischemia-reperfusion injury, reducing tissue edema and inflammatory leukocyte infiltration.
Anti-Thrombotic Properties: Prostacyclin (PGI2) and thrombomodulin expression creates an anti-coagulant surface preventing microvascular thrombosis in ischemic conditions.
Biomarkers
Key Biomarkers & Molecular Cargo
| Marker / Molecule | Functional Role |
|---|---|
| CD31 (PECAM-1) | Endothelial identity; mediates cell-cell adhesion in new vessel formation |
| VE-Cadherin (CD144) | Adherens junction protein; endothelial barrier integrity |
| vWF (von Willebrand Factor) | Endothelial-specific secretory marker; coagulation platform |
| eNOS | Nitric oxide synthase; vasoprotective NO production, blood pressure regulation |
| VEGFR2 (KDR) | Primary VEGF receptor; angiogenic signaling hub |
| VEGF-A / Ang-1 / PDGF | Angiogenic paracrine growth factors |
| Prostacyclin (PGI2) | Anti-thrombotic and vasodilatory eicosanoid |
| miR-126 | Endothelial-specific miRNA; VEGF signaling, vascular integrity maintenance |
Applications
Therapeutic Applications
- Peripheral Artery Disease (PAD) — therapeutic angiogenesis, critical limb ischemia
- Ischemic Stroke — cerebrovascular repair, BBB restoration
- Hypertension — eNOS restoration, vascular smooth muscle relaxation
- Erectile Dysfunction — penile microvascular regeneration, NO pathway restoration
- Chronic Wound Healing (diabetic ulcers, venous ulcers) — neovascularization of wound bed
- Microcirculation Disorders — Raynaud's phenomenon, small vessel disease
- Diabetic Angiopathy — retinal, renal, and peripheral vascular bed repair
- Post-MI Revascularization — coronary microvascular repair adjunct
Evidence
Clinical & Preclinical Evidence
In hindlimb ischemia models (PAD simulation), intra-arterial injection of UCT-MSC-derived endothelial cells achieved 75% limb salvage rate vs 30% in controls, with laser Doppler perfusion ratios recovering to 0.85 (vs 0.95 normal) at 4 weeks. CD31+ vessel density in ischemic muscle was 3.2× higher in treated vs control limbs.
In hypertensive rat models (SHR), IV infusion of endothelial cells derived from MSCs normalized systolic blood pressure by 18–22 mmHg, restored endothelium-dependent vasodilation (ACh response 85% of normotensive controls), and reduced aortic wall thickness by 25% — confirming vascular remodeling reversal.
For erectile dysfunction, mechanistic studies confirm that eNOS-expressing endothelial cells restore corpus cavernosal NO levels, smooth muscle relaxation, and penile hemodynamics in diabetic ED models. This forms the biological basis for the Akira Endothelial Cell and Endothelial Exosome products in the P-Shot MAX formulation.
A 2023 review of MSC-derived exosomes containing endothelial cargo (VEGF, miR-126, eNOS, angiopoietins) confirmed efficacy in peripheral artery disease, ischemic stroke, and wound healing preclinical models — mechanistically validating the Akira Endothelial Exosome product.[2]
UCT-WJ-MSCs differentiate into endothelial cells with higher angiogenic index scores than adult-source MSCs in Matrigel tube formation assays (total tube length, branch points, and enclosed areas all significantly greater at matched passage numbers), confirming the production quality advantage of Akira's donor selection.